Indications
Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III and IV.
Composition
- Active substance
- sotatercept
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Winrevair
- Active substance
- sotatercept
- ATC code
- C02KX06
- Therapeutic area
- Hypertension, Pulmonary
- Marketing authorisation holder
- Merck Sharp & Dohme B.V.
- Status
- Authorised
- EU authorisation